Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
Maria Vittoria Dieci(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Roberto D’Amico(University of Modena and Reggio Emilia), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Michela Donadio(Azienda Ospedaliero Universitaria San Giovanni Battista), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Viviana Bazan(University of Palermo), Valentina Guarneri(Istituto Oncologico Veneto), Gabriella Moretti(Istituti di Ricovero e Cura a Carattere Scientifico), Maria Pia Foschini(Ospedale Bellaria), Alessandra Beano(Presidio Ospedaliero), Sara Balduzzi(Dutch Cancer Society), Héctor Soto Parrà, Giancarlo Bisagni, Roberto Vicini, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), Francesco Giotta(Istituto Tumori Bari), Gaia Griguolo(University of North Carolina at Chapel Hill), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonella Ferro(Ospedale Santa Chiara), Saverio Danese(Ospedale Sant'Anna), Vittorio Gebbia(La Maddalena), Laura Amaducci(Ospedale degli Infermi), S. Romito(Ospedali Riuniti di Foggia), Michele Aieta(Centro di Riferimento Oncologico della Basilicata)
Cited by 25
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879